Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 2/5.

Maternal morbidity and mortality continue to rise in the United States, with cardiovascular disease as the leading cause of maternal deaths. Congenital heart disease is now the most common cardiovascular condition encountered during pregnancy, and its prevalence will continue to grow. In tandem with these trends, maternal cardiovascular health is becoming increasingly complex. The identification of women at highest risk for cardiovascular complications is essential, and a team-based approach is recommended to optimize maternal and fetal outcomes. This document, the second of a 5-part series, will provide practical guidance from pre-conception through postpartum for cardiovascular conditions that are predominantly congenital or heritable in nature, including aortopathies, congenital heart disease, pulmonary hypertension, and valvular heart disease.
Competing Interests: Funding Support and Author Disclosures Dr. Bairey Merz has served as a consultant for Abbott and Sanofi; and has served on the Board of Directors for iRhythm. Dr. Bello is supported by the National Institutes of Health/National Heart, Lung, and Blood Institute (K23 HL136853-03, R01 HL153382-01). Dr. Gomberg-Maitland has received research grant support to GWU-MFA from Acceleron, Bayer, Complexa, and United Therapeutics; and has served as a consultant for Actelion, Altavant, Acceleron, Bayer, Gilead, Insemed, Reata, and United Therapeutics. Dr. Park has served as a consultant for Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)